Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Not Confirmed
Not Confirmed
20-23 July, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
APGA Annual ConferenceAPGA Annual Conference
Industry Trade Show
Not Confirmed
20-23 July, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
26 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/26/3105718/0/en/Revive-Therapeutics-Nears-Completion-of-Key-Nerve-Agent-Countermeasure-Study-with-Canadian-Department-of-National-Defence-Highlighting-Significant-Stockpiling-Opportunity.html
04 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/04/3093409/0/en/Revive-Therapeutics-Advances-with-Next-Generation-Bucillamine-Development.html
21 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/21/3065006/0/en/Revive-Therapeutics-Announces-Proposed-Shares-for-Debt-Transaction.html
10 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/10/3059109/0/en/Revive-Therapeutics-to-Investigate-Bucillamine-s-Potential-in-Cancer-Treatment.html
01 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/01/3053212/0/en/Revive-Therapeutics-Announces-Acquisition-of-Molecular-Hydrogen-Program.html
28 Mar 2025
// FDA
ABOUT THIS PAGE